The weight loss drug conversation has been accelerating for years – from the early Ozempic headlines through the Wegovy wave ...

Eli Lilly's new experimental weight loss drug retatrutide yielded up to 28% weight loss, which is greater than that of ...

While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors ...

Retatrutide helped people lose 70 pounds on average, or 28% of their body weight, in a clinical trial. The Eli Lilly weight-loss drug mimics three gut hormones.

Retatrutide, Eli Lilly’s new experimental drug, helped some participants lose up to 28 percent of their body weight in clinical trials.

The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug ...

Retatrutide, Eli Lilly’s next obesity shot, showed far more weight loss in clinical trial patients than other blockbuster ...

The latest clinical trial results for retatrutide suggest this experimental drug could help adults with obesity shed more ...

Retatrutide altered circulating metabolites and lipids linked to fatty acid oxidation and insulin resistance in people with ...